SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?

Affiliations

• ¹ Department of Medicine and Health Sciences "Vincenzo Tiberio", Campobasso 86100, Italy; Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Neuroimmunology and Inflammation (INI), Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York, NY, USA; Casa di Cura Montevergine, Mercogliano (Avellino), Italy. Electronic address: pasquale.mone@unimol.it.
• ² Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi (Salerno), Italy.
• ³ Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Neuroimmunology and Inflammation (INI), Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York, NY, USA.
• ⁴ Department of Medicine and Health Sciences "Vincenzo Tiberio", Campobasso 86100, Italy; International Translational Research and Medical Education Consortium (ITME), Academic Research Unit, Naples, Italy.
• ⁵ Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Einstein Institute for Neuroimmunology and Inflammation (INI), Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York, NY, USA; International Translational Research and Medical Education Consortium (ITME), Academic Research Unit, Naples, Italy; Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.